← Leaderboards
Benjamin L Handen
University Of Pittsburgh At Pittsburgh
$48,952,794
Attributed
$65,880,994
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $30.5M · FY2008–25$50M$37.5M$25M$12.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$169,546,358 · 14
By mechanism
U19$135,462,225 · 6
U01$24,124,468 · 2
R01$6,520,048 · 2
P50$2,123,360 · 2
R25$866,506 · 1
R21$449,751 · 1
Top collaborators
- Bradley T Christian21 shared
- Elizabeth Head12 shared
- William E Klunk11 shared
- Mark Mapstone11 shared
- Ann D. Cohen1 shared
- John N Constantino1 shared
- Sigan L Hartley1 shared
- Christy Hom1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- William E Klunk$26,129,826
- Kimberly Howard-Quijano$812,700
- Brooke S.g. Molina$32,831,004
- Amantha Thathiah$4,460,443
- Kirill Kiselyov$3,406,970
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposCohortAdultS DiseaseDown SyndromeBiological MarkersResearch PersonnelCognitiveParticipantNeuropathologyProtocols DocumentationHigh RiskGeneticAmyloidSymptomsDementiaPositron-Emission TomographyNeuroimagingRecruitSenile PlaquesAlzheimerâS Disease BiomarkerUniversitiesGeneral PopulationFunding
Grant awards (62)
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$17,980,649
U19 · FY2025 · AG · contact PI
Core C: Clinical Core$5,250,122
U19 · FY2025 · AG · contact PI
Core A: Administrative Core$922,002
U19 · FY2025 · AG · contact PI
INCLUDE Clinical Researcher Training (ICRT)$866,506
R25 · FY2025 · AG
Mental Health in Autistic Adults: An RDoC Approach$528,616
P50 · FY2025 · MH · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$404,804
U19 · FY2025 · AG · contact PI
Metabolic Health, Lifestyle, and Risk of Co-Occurring Health Conditions in Down Syndrome (MET-DS)$2,800,027
U01 · FY2024 · HD
Mental Health in Autistic Adults: An RDoC Approach$543,075
P50 · FY2024 · MH · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$21,776,522
U19 · FY2023 · AG · contact PI
Core C: Clinical Core$5,422,290
U19 · FY2023 · AG · contact PI
Core A: Administrative Core$1,311,852
U19 · FY2023 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS) - KUMC Field Site Supplement$774,896
U19 · FY2023 · AG · contact PI
Mental Health in Autistic Adults: An RDoC Approach$541,485
P50 · FY2023 · MH · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS) - Supplement$438,809
U19 · FY2023 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$19,233,560
U19 · FY2022 · AG · contact PI
Core C: Clinical Core$5,359,734
U19 · FY2022 · AG · contact PI
Core A: Administrative Core$1,164,446
U19 · FY2022 · AG · contact PI
ABC-DS MOMsâ Supplement (Modification of Maternal AD risk in DS)$788,668
U19 · FY2022 · AG · contact PI
Core C: Clinical Core$788,668
U19 · FY2022 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)-04 Supplement 5$765,262
U19 · FY2022 · AG · contact PI
Core A: Administrative Core$765,262
U19 · FY2022 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$739,002
U19 · FY2022 · AG · contact PI
Mental Health in Autistic Adults: An RDoC Approach$510,184
P50 · FY2022 · MH · contact PI
Core A: Administrative Core$177,627
U19 · FY2022 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)-04 Supplement 4$177,627
U19 · FY2022 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$19,355,148
U19 · FY2021 · AG · contact PI
Core C: Clinical Core$5,290,290
U19 · FY2021 · AG · contact PI
Core A: Administrative Core$1,148,484
U19 · FY2021 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$250,000
U19 · FY2021 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$20,980,417
U19 · FY2020 · AG · contact PI
Core A: Administrative Core$2,098,042
U19 · FY2020 · AG · contact PI
Core C: Clinical Core$2,098,042
U19 · FY2020 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$4,277,120
U01 · FY2019 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$586,856
U01 · FY2019 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease â Supplement Loni Harmonization$423,907
U01 · FY2019 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease - Supplement 1 MRI-PET$311,377
U01 · FY2019 · AG · contact PI
NiAD Supplement WashU Start Up$237,306
U01 · FY2019 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$3,742,475
U01 · FY2018 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$386,628
U01 · FY2018 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$129,573
U01 · FY2018 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$69,940
U01 · FY2018 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$3,623,562
U01 · FY2017 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$163,334
U01 · FY2017 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$158,939
U01 · FY2017 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$3,556,865
U01 · FY2016 · AG · contact PI
Natural History of Amyloid Deposition in adults with Down Syndrome$739,845
R01 · FY2016 · AG · contact PI
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$3,656,559
U01 · FY2015 · AG · contact PI
Natural History of Amyloid Deposition in adults with Down Syndrome$752,386
R01 · FY2015 · AG · contact PI
Natural History of Amyloid Deposition in adults with Down Syndrome$579,286
R01 · FY2014 · AG · contact PI
Natural History of Amyloid Deposition in Adults with Down Syndrome$235,826
R01 · FY2014 · AG · contact PI
Natural History of Amyloid Deposition in adults with Down Syndrome$546,303
R01 · FY2013 · AG · contact PI
Natural History of Amyloid Deposition in adults with Down Syndrome$617,267
R01 · FY2012 · AG · contact PI
1/3-Atomoxetine Placebo and Parent Training in Autism$269,976
R01 · FY2012 · MH · contact PI
1/3-Atomoxetine Placebo and Parent Training in Autism$269,971
R01 · FY2011 · MH · contact PI
Natural History of Amyloid Deposition in Adults with Down Syndrome$879,621
R01 · FY2010 · AG · contact PI
1/3-Atomoxetine Placebo and Parent Training in Autism$272,700
R01 · FY2010 · MH · contact PI
Natural History of Amyloid Deposition in Adults with Down Syndrome$811,917
R01 · FY2009 · AG · contact PI
1/3-Atomoxetine Placebo and Parent Training in Autism$272,698
R01 · FY2009 · MH · contact PI
1/3-Atomoxetine Placebo and Parent Training in Autism$272,252
R01 · FY2008 · MH · contact PI
Donepezil HCL: Treating Cognitive Deficit in Autism$149,917
R21 · FY2003 · MH
Donepezil HCL: Treating Cognitive Deficit in Autism$149,917
R21 · FY2002 · MH
Donepezil HCL: Treating Cognitive Deficit in Autism$149,917
R21 · FY2001 · MH